

Review

Open Access

## Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consecutive series of unselected patients

Roberto Biffi\*<sup>†1</sup>, Hugo Marsiglia<sup>†2,3</sup>, Barbara Jereczek Fossa<sup>†2</sup>, Maria Cristina Leonardi<sup>†2</sup>, Domenico Cante<sup>†2</sup>, Roberta Lazzari<sup>†2</sup>, Antonio Chiappa<sup>†1</sup>, Sabine Cenciarelli<sup>†1</sup>, Bruno Andreoni<sup>†1</sup>, Maria Giulia Zampino<sup>†4</sup> and Roberto Orecchia<sup>†2</sup>

Address: <sup>1</sup>Dept. of General Surgery-European Institute of Oncology and University of Milano, Via Ripamonti, 435, Italy, <sup>2</sup>Dept. of Radiotherapy-European Institute of Oncology and University of Milano, Via Ripamonti, 435, Italy, <sup>3</sup>Dept. of Radiotherapy, Institute Gustav Roussy, Villejuif, France and <sup>4</sup>Dept. Of Oncology-European Institute of Oncology-Milano, Via Ripamonti, 435. Italy

Email: Roberto Biffi\* - roberto.biffi@ieo.it; Hugo Marsiglia - roberto.biffi@ieo.it; Barbara Jereczek Fossa - barbara.fossa@ieo.it; Maria Cristina Leonardi - mariacristina.leonardi@ieo.it; Domenico Cante - roberto.biffi@ieo.it; Roberta Lazzari - roberta.lazzari@ieo.it; Antonio Chiappa - antonio.chiappa@unimi.it; Sabine Cenciarelli - sabine.cenciarelli@ieo.it; Bruno Andreoni - bruno.andreoni@ieo.it; Maria Giulia Zampino - mariagiuliazampino@ieo.it; Roberto Orecchia - roberto.orecchia@ieo.it

\* Corresponding author †Equal contributors

Published: 20 September 2007

Received: 18 January 2007

*International Seminars in Surgical Oncology* 2007, **4**:23 doi:10.1186/1477-7800-4-23

Accepted: 20 September 2007

This article is available from: <http://www.issoonline.com/content/4/1/23>

© 2007 Biffi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** although preoperative RT (Radiation Therapy) is becoming the preferred approach for combined treatment of locally advanced rectal adenocarcinoma, no regimen can be now considered as a standard. Since the toxicity of preoperative RT isn't yet completely known, and the advantages of preoperative RT could be counterbalanced by increased postoperative morbidity and mortality, a monocentre series of preoperative bifractionated accelerated RT was retrospectively reviewed to clarify toxicity and outcomes after a prolonged follow up.

**Methods:** patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3–4/anyN, or anyT/N1–2; ECOG Performance Status 0–2. A total dose of 41.6 Gy (26 twice daily fractions of 1.6 Gy) was delivered. Surgery was carried out 17 ± 2 days after RT completion, adopting the total mesorectal excision technique.

**Results:** 24 men and 23 women were enrolled; median age was 55 years (r.: 39–77). Twenty-eight patients were stage II and 19 stage III. 9 patients suffered from a recurrent tumour. 2 patients experienced a severe grade 4 gastrointestinal toxicity (a colo-vaginal fistula and an intestinal obstruction, both successfully treated). Operative mortality was nil; postoperative early complications occurred in 13 cases; mean length of hospital stay was 15 days. After a mean follow up of 44 months (r.: 18–84) 8 patients had deceased for recurrent disease, 15 were alive with a disease progression (2 pelvic recurrences and 13 pure distant deposits) and 24 were alive, without disease. The 5-year actuarial overall survival was 74.2%, the disease-free survival 62.9% and the regional control rate 84.7%. Long-term complications included 1 case of radiation enteritis requiring surgery, 2 cases of anastomotic stricture and 3 cases of bladder incontinence.

**Conclusion:** bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable. These findings support the increasing use of preoperative RT for treatment of this malignancy in experienced centres. Ongoing multicentric trials are expected to address still unsolved issues, including the benefit of CT adjunct to preoperative RT.

---

## Background

Surgery remains the primary modality of treatment for rectal cancer and is the only therapy required for early-stage disease. Locally advanced rectal adenocarcinoma (i.e. resectable cancer with transmural spread and/or lymphatic nodes involvement) continues indeed to represent a major challenge to surgeons. Although remarkable progress has been made during the past two decades in improving surgical techniques, tumours in the lower half of the rectum pose specific technical problems, and a radical R0 resection of the tumour and its lymphatic component may be difficult to obtain, especially when a huge lesion is located in a very narrow pelvis of a male patient. Several studies have recently focused attention on the importance of standardized surgical technique of total mesorectal excision [1,2] as well as its integration with chemo-(CT) and radiation therapy (RT) for optimal treatment of this malignancy [3,4]. Although preoperative RT is becoming the preferred approach to locally advanced rectal cancer in many Institutions and large randomised trials have shown that preoperative RT can substantially decrease local failure rates and slightly improve overall survival [5,6], no RT regimen can be now considered as a standard, and ongoing studies are still addressing some major unresolved issues, including the optimal timing of RT (preop- vs postoperative) and the relative merits of short vs long-course RT. A major concern raised from a recent meta-analysis, showing a consistent increase in noncancer-related mortality for patients receiving preoperative RT [7]; since the toxicity of preoperative RT seems to be not yet completely known, and the advantages of preoperative RT could be counterbalanced by increased postoperative morbidity and mortality, as seen in some trials [8], we decided to retrospectively review our series of preoperative bi-fractionated accelerated RT in locally advanced rectal cancer, in the attempt to identify risk factors for early and late toxicity (if any), and to define most significant oncologic and functional outcomes after a prolonged follow up.

## Methods

After being informed and giving their consent, 47 consecutive patients from the European Institute of Oncology in Milan were enrolled in this study. The eligibility criteria included the following: histology-proven adenocarcinoma of the rectum; distal tumour extent within 12 cm

from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2 for primary or recurrent disease as well; no evidence of distant deposits; ECOG Performance Status 0-2; age >18 years; no prior or concurrent malignancy, and finally no prior RT. Adjuvant CT was allowed for eligible patients, suffering from recurrent carcinoma of the rectum.

Pre-treatment evaluation included complete physical examination, digital rectal examination, common laboratory biochemical test, CEA (Carcinoembryonic Antigen) determination, colonoscopy, CT-scan (Computerized Tomography) of the thorax, abdomen and pelvis, and EUS (endoscopic rectal ultrasonography). Total dose delivered was 41.6 Gy in 26 fractions of 1.6 Gy, two times daily with at least a 6-h interval. The target volume included the tumour and each enlarged lymph node (if any), with a margin of at least 3 cm, perirectal and internal iliac lymph nodes, the presacral area and surrounding organs considered to be involved by tumour. A four-field technique (box) was always used. Dosimetry was optimised by means of a treatment-planning computerized program, on the basis of either patient's contours or dosimetric CT scan. High energy photons of at least 15 MV were used.

Surgery was scheduled after a rest period of  $17 \pm 2$  days from RT completion. Total mesorectal excision technique was always adopted. Adjuvant CT (5 FU + Folinic Acid bolus) for a 6-month period was planned for patients who had T4 or N+ at pathology report of surgical specimen.

## Results

Table 1 summarizes patients' population pertinent characteristics. 47 patients were treated (24 men and 23 women); the median age was 55 years (r.: 39-77). Pre-treatment clinical staging included 28 cases stage II and 19 stage III. 9 patients suffered from a recurrent tumour. Median distance between the lower tumour edge and the anal verge was 5 cm (range: < 1 - 12).

Three patients did not complete the planned RT schedule as a consequence of early toxicity; in these cases the dose administered was 32, 40 and 40.8 Gy respectively.

Table 2 shows the observed toxicity; severe grade 4 gastrointestinal reactions included a colo-vaginal fistula,

**Table 1: patients' population pertinent characteristics**

No. of patients treated	47
Male: Female ratio	24 : 23
Mean age (range)	55 yrs. (39–77)
Primary tumours : recurrences ratio	38 : 9
cTNM Stage II : stage III ratio	28 : 19
Mean distance between tumour edge and anal verge (range)	5.0 cm (<1 – 12)
No. of patients who completed RT programme as protocol	44 (93.6%)

while 1 patient suffered from grade 3 toxicity (intestinal sub-obstruction). Both were successfully treated. 9 cases of grade 2 and 19 cases of grade 1 gastrointestinal reactions were detected. One case of grade 2 and 15 cases of grade 1 urogenital morbidity were observed. 6 cases of grade 2 and 6 cases of grade 1 haematological toxicity occurred. Finally, one grade 2 and 7 grade 1 skin toxicity were observed.

Surgery was performed at a mean interval of  $17 \pm 2$  days after RT completion, always adopting the total mesorectal excision technique. Table 3 lists the main surgical features; abdomino-perineal resection (APR) was carried out in 14 patients, and low anterior resection with mechanical anastomosis in 33. 16 patients had blood peroperative transfusions; a mean of 2 units of packed red blood cells were administered (r. = 0–5). All operated patients could benefit of a curative surgery, expressed by an R0 procedure (proximal, distal and circumferential margins free of disease; the circumferential free margin resulted less than 1 mm in 9 cases).

None patient obtained a complete pathology response to the treatment. Downstaging, expressed as pathologic ypT1–2, ypN0 stage, occurred in 3 patients only. A post-RT pathology stage ypT1 was detected in 1 case, ypT2 in 7, ypT3 in 33 and ypT4 in 6. Positive nodes were detected in 33 patients. Mean length of hospital stay was 15 days (range: 8–35). YpT4-any N and N positive patients under-

**Table 2: observed acute toxicity from preoperative radiation therapy**

Type	Grade 1	Grade 2	Grade 3	Grade 4
Gastrointestinal	19	9	I (intestinal obstruction)*	I (colovaginal fistula)**
Urogenital	15	1	-	-
Haematologic	6	6	-	-
Skin	7	1	-	-

\* successful conservative treatment; \*\* successful en-bloc resection at the time of programmed surgery

**Table 3: main surgical and pathology features in 47 operated patients**

Parameter	No.	%
Low anterior resection	33	70.2
Abdomino-perineal resection	14	29.8
En-bloc resection of other organs	5	10.6
R-0 operation Circumferential free margin < 1 mm	47	100
Circumferential free margin < 1 mm	9	19.1
Patients having blood peroperative transfusions (mean: 2 PRBC; r: 0–5)	9	19.1
Downstaging (ypT1–2 ypN0)	3	6.3
ypT1 – ypT2	8	17.0
ypT3 – ypT4	39	83.0
Mean length of hospital stay (days; r)	15	(8–35)

went adjuvant chemotherapy for a median of 6 months (5 FU + Folinic Acid bolus).

Postoperative complications occurred in 13 cases (a detailed list is presented in Table 4): two anastomotic leaks (both requiring a re-operation), two cases of prolonged postoperative ileus, one pelvic abscess (causative agent: *P. aeruginosa*) and eight cases of surgical site infection (SSI) grade I-II, according to CDC classification (perineal and/or laparotomy wound).

After a mean follow up of 44 months (range: 18–84) (Table 5), six patients experienced severe late complications: three cases of grade 3 gastrointestinal toxicity (1 radiation enteritis requiring surgery and 2 cases of anastomotic stricture requiring serial endoscopic dilatations) and three cases of grade 3 urogenital toxicity (vesical incontinence). No case of severe cardiovascular toxicity occurred. 8 patients (6 of them affected from recurrence of previous rectal cancer) had deceased for recurrent disease (pelvic recurrence and concomitant distant metastases), 15 were alive with a disease progression (2 pelvic recurrences and 13 pure distant deposits) and 24 were alive, without disease. The 5 year actuarial overall survival was 74.2%, the disease-free survival 62.9% and the regional control rate 84.7%.

**Table 4: postoperative early complications**

Type	No. of cases	%
Anastomotic leak	2 (out of 33)	6.0
Prolonged postoperative ileus	2 (out of 47)	4.2
Abdominal abscess	1 (out of 47)	2.1
Surgical site infections (grade I-II)*	8 (out of 47)	17.0
All	13 (out of 47)	27.6

\*according to CDC classification of Surgical Site Infections

**Table 5: long term results (mean follow up: 44 mo., n = 18–84)**

Parameter	No.	%
Deceased (progression of disease)	8	17.0
Primary tumour	2	25
Recurrent disease	6	75
Alive without disease	24	51.0
Alive with disease	15	31.9
Overall local recurrences	10	21.2
Pure distant metastases	13*	27.6
Urogenital toxicity – grade 3	3**	6.3
Gastrointestinal toxicity – grade 3	3***	6.3

\* liver 7 cases, lung 4 cases, peritoneum and lymphnodes 2 cases

\*\* bladder incontinence

\*\*\* 1 case of radiation enteritis requiring surgery, 2 cases of anastomotic stricture requiring serial endoscopic dilatations

## Discussion

At present, a variety of innovative RT schedules aiming at obtaining minimal treatment toxicity are being tested, including preoperative bi-fractionated accelerated RT. Theoretic common advantages of long- and short-course of preoperative RT include the better tumour radio sensitivity, coming from improved oxygenation of presurgical field, the reduction in tumour seeding by surgical handling and perhaps the reduced toxicity, due to the lesser amount of radiated small bowel. A recent meta-analysis of studies dealing with adjuvant RT for rectal cancer, including over 8,000 patients, has reported a reduction of local recurrence risk by almost 50% by preoperative treatment, independently from fractionation schedules, compared to 37% of risk reduction for postoperative RT [7]. Practical and economic considerations provided a major effort for developing short-course treatments, as the tumoricidal effect of short-course RT (25 Gy in one week) seems to be equal to that of long-course (42 to 50 Gy over four to six weeks), using a variety of schedules [9-11]. Unfortunately, a single randomised study has compared preoperative short-course with postoperative RT, delivered over 8 weeks [12]; the reduced local recurrence rate with the former does not mean an inherent superiority of short vs long-course and adds little to the debate regarding this issue. However, a major concern could be the price for short-course preoperative RT, in terms of increased short- and long-term toxicity, as previously observed with short-course RT at other sites. This concern has been highlighted in the above mentioned meta-analysis, which showed a significant increase in noncancer-related mortality at one year of follow up, mainly as a consequence of cardiovascular events in older patients [7]. We did not observe sim-

ilar events in our experience, and is likely that could be the result of outdated techniques, as there was no increase in postoperative mortality in patients receiving preoperative RT according to modern techniques in either the Swedish Rectal Cancer Trial or the Dutch Trial. With respect to early toxicity, the investigators from the Swedish trial reported an increased frequency of postoperative fistulas and femoral neck and pelvic fractures; moreover, for patients who underwent a conservative surgery, a significantly altered residual sphincter function was found [5]. The Dutch group reported an increase in perineal complications (essentially infectious) in patients receiving preoperative RT compared to surgery alone controls [6]. Our own data confirm these findings: the vast majority of early observed toxicity is related to infectious complications of surgical wounds, whereas anastomotic leaks and pelvic abscess are less relevant.

Our single case of late small bowel toxicity confirms another previous evidence, coming from randomised trials and retrospective experiences, that preop-RT may have fewer adverse effects on long-term bowel function than postoperative therapy [13,14]. One possible explanation could be the fact that the radiated rectosigmoid is removed after neoadjuvant therapy; moreover, this could be the result of a lower radiation dosage to the small bowel, as it is much easier to exclude the small intestine from the radiation field in a pelvis free of surgical adhesions by proper positioning of the patients [15]. Moreover, postoperative treatment is associated with increased frequency of bowel movements per day, higher rate of incontinence and increased use of antidiarrhea medications [16]. In addition, a large German multi-institutional study reported that only 37% of expected patients were referred for postoperative adjuvant treatment, reflecting a surgeons' policy based on patients' individual risk factors evaluation instead of TNM stage [17]. In our non-randomised study, no patients who were continent before treatment developed incontinence, thus comparing favourably with the incontinence rates associated with postoperative adjuvant treatment.

A possible benefit of preoperative therapy is the potential for downstaging, thus increasing resectability rate and the possibility of sphincter-preserving surgery. Although the extent of downstaging appears related to the time interval between completion of preop RT and surgery, the two major studies of preoperative radiation therapy in rectal cancer (Swedish [5] and Dutch [6] trials) scheduled surgery after 1 week and 10 days respectively after the end of radiation treatment; moreover, in the Swedish trial more patients in the preoperative RT group had Dukes stage A or B cancers, whereas in our series only patients with locally advanced or recurrent disease have been treated. In the larger Dutch study no difference in the rates of positive

circumferential margins has been detected (16% in the preoperative RT vs 19% of surgery alone); our own data confirm this evidence: a short course of preop-RT and a short time-interval before surgery are not able to produce a significant pathologic downstaging, and complete responses should not be expected. Our finding of 9 out of 47 patients with minimal circumferential free margin at surgery (less than 1 mm) confirms that the biological effect of radiation can extend beyond the anatomic boundaries of the lesion, with minimal damage to surrounding normal tissues.

Minsky et al. studied 22 patients with distal rectal cancers that had been deemed to require APR for cure, and found that preoperative RT resulted in significant tumour downstaging, enabling approximately 90% of patients to undergo sphincter preservation surgery [18]. Similarly, Rouanet et al. used preoperative irradiation to treat 37 patients with rectal cancer that was thought to require an APR [19]; sphincter salvage was possible in 78% of patients. Francois and co-workers [20], in the only study specifically designed to explore this issue, randomised a total of 201 patients to either surgery after 2 weeks or after 6–8 weeks from the completion of the RT; both clinical and pathologic downstaging were significantly higher in the longer interval group.

Nonetheless, it's our opinion that achieving a microscopic tumour-free circumferential margin is an important factor affecting local pelvic recurrence, and the surgeon's ability to obtain tumour clearance can be challenged by the physical constraints of a narrow pelvis, particularly in male patients. A short course of preop-RT offers the advantage of decreasing the size ("downsizing") of the tumour before surgery, increasing the resectability rate of lesions which were previously deemed unresectable with curative intent or at high risk of R1–R2 procedures. In our series, patients with recurrent tumours and those with huge masses deeply invading the mesorectum had local recurrence rates that remain very high, in spite of preoperative RT administration; that's why our efforts are now directed to obtain a better local control of these huge lesions by means of combined preoperative CT-RT treatment, using higher doses and longer time interval, in agreement with other groups' reported experiences [21].

## Conclusion

In conclusion, bi-fractionated accelerated RT administered in the preoperative setting to patients suffering from locally advanced rectal cancer was safe in terms of early and long-term toxicity, the latter being expressed as acceptably low postoperative complications' rate (mainly infectious) and toxic effects on small bowel. These findings support the increasing use of preoperative RT in the treatment of locally advanced rectal carcinoma; ongoing

trials are expected to address major unsolved issues, including the role of combined modality treatment (RT plus CT) in the preoperative setting.

## References

- Porter GA, Soskolne CL, Yakimetes WW, Newman SC: **Surgeon-related factors and outcome in rectal cancer.** *Ann Surg* 1998, **227**:157-67.
- Martling AL, Holm T, Rutqvist LE, Moran BJ: **Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project.** *Lancet* 2000, **356**:93-6.
- Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler H, Prager D, Cruz AB Jr, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rochette H, Fisher B: **Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.** *J Natl Cancer Inst* 2000, **92**:388-96.
- O'Connell MJ, Martenson JA, Wieand HS, Krook JE, McDonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA: **Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.** *N Engl J Med* 1994, **331**:502-7.
- Anonymous: **Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial.** *N Engl J Med* 1997, **336**:980-7.
- Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ: **Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.** *N Engl J Med* 2001, **345**:638-46.
- Colorectal Cancer Collaborative Group: **Adjuvant radiotherapy for rectal cancer: a systematic review of 8507 patients from 22 randomized trials.** *Lancet* 2001, **358**:1291-304.
- Holm T, Rutqvist LE, Johansson H, Cedermark B: **Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: Causes and risk factors.** *Br J Surg* 1996, **83**:964-8.
- Kirk J, Gray WM, Watson ER: **Cumulative radiation effect. I. Fractionated treatment regimens.** *Clin Radiol* 1971, **22**:145-55.
- Turesson I, Notter G: **The influence of fraction size in radiotherapy on the late normal tissue reaction-I: Comparison of the effects of daily and once-a-week fractionation on human skin.** *Int J Radiat Oncol Biol Phys* 1984, **10**:593-8.
- Fowler JF: **The linear-quadratic formula and progress in fractionated radiotherapy.** *Br J Radiol* 1989, **62**:679-94.
- Pahlman L, Glimelius B: **Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.** *Ann Surg* 1990, **211**:187-95.
- Paty PB, Enker WE, Cohen AM, Lauwers GY: **Long-term functional results of coloanal anastomosis for rectal cancer.** *Am J Surg* 1994, **167**:90-5.
- Birnbaum EH, Dreznik Z, Myerson RJ, Lacey DL, Fry RD, Kodner IJ, Fleshman JW: **Early effect of external beam radiation therapy on the anal sphincter: a study using anal manometry and transrectal ultrasound.** *Dis Colon Rectum* 1992, **35**:757-61.
- Abdelkarim SA, Bischof S, Nuet P: **Impact of the <<Belly Board>> Device on treatment reproducibility in preoperative radiotherapy for rectal cancer.** *Strahlenther Onkol* 2002, **178**:259-62.
- Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Ilstrup DM: **The long term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function.** *Ann Surg* 1994, **220**:576-82.
- Wulf J, Kramer K, van Aaken C, Dietzel F, Lucas D, Pfander K, Schimpke T, Schulze W, Thiel HJ, Zieger K, Flentje M: **Outcome of postoperative treatment for rectal cancer UICC stage II and III in day-to-day clinical practice. Results from a retrospective quality control analysis in six institutions in North Bavaria (Germany).** *Strahlenther Onkol* 2004, **180**:5-14.
- Minsky BD, Cohen AM, Enker WE, Kelsen DP, Kemeny N, Riechman B, Saltz L, Sigurdson ER, Frankel J: **Phase III trial of preoperative radiation therapy and coloanal anastomosis in distal invasive**

- resectable rectal cancer.** *Int J Radiat Oncol Biol Phys* 1992, **23**:387-92.
19. Rouanet P, Farber JM: **Conservative surgery for low rectal carcinoma after high dose radiation. Functional and oncologic results.** *Ann Surg* 1995, **221**:67-73.
  20. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souguet JC, Adeleine P, Gerard JP: **Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial.** *J Clin Oncol* 1999, **17**:2396.
  21. Rullier E, Goffre B, Bonnel C, Zerbib F, Caudry M, Saric J: **Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum.** *Ann Surg* 2001, **234**:633-40.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

